Medium materiality6/10
Wells Fargo Starts Denali Therapeutics at Overweight
Why it may matterVerify against the original reporting
Bullish analyst initiation with substantial implied upside; treat the target as an opinion rather than a forecast.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Wells Fargo initiated coverage of DNLI at Overweight with a $35 target, about 85% above the posted price of $18.89. This is a bullish analyst opinion, not a guaranteed outcome.
- Wells Fargo initiated DNLI at Overweight with a $35 target versus a posted price of $18.89.
Key facts
- 01
Target: $35
- 02
Posted price: $18.89
- 03
Analyst firm: Wells Fargo
- 04
Analyst: Benjamin Burnett
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.